Category: News

For Immediate Release May 13, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development, and  commercialization of oncology and antiviral drugs, announced that it has filed its 2021 first quarter report. The Report shows that the Company had Cash & Cash Equivalents of $1,796,596 as of  March 31, 2021, the period end. 

The following is a summary of the Report highlights: 

On January 26, 2021, the Company received a Notice of Allowance from the Canadian Intellectual  Property Office for a new patent application covering Adva-27a. The newly issued patent contains  new subject matter and extends the proprietary protection of Adva-27a in Canada until 2033. 

On February 4, 2021, the Company entered into an exclusive license agreement with the  University of Georgia (“UGA”) for two Anti-Coronavirus compounds which UGA had previously  developed and patented. The Company and UGA will advance the development of these two  compounds in parallel with the Company’s own Anti-Coronavirus compound, SBFM-PL4. 

On March 1, 2021, the Company launched a new eCommerce website,  Nutrition.SunshineBiopharma.com. The site offers over 20 Science-Based Nutritional  Supplements products ranging from essential amino acids and rich protein powders to balanced  vitamins and crucial micronutrients. All of the Company’s Science-Based Nutritional Supplements  are manufactured and tested in Canada under GMP conditions. 

On March 9, 2021, the Company received a Notice of Allowance from the European Patent Office  for a new patent application covering Adva-27a. The newly issued patent contains new subject  matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent  patent in the United States was issued in 2019 (US Patent Number 10,272,065). 

Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are incredibly pleased with the  progress of our Company as a whole. We continue to receive positive interim results from the  University of Georgia regarding our mice study and the development of our Anti-Coronavirus  treatment, and are very happy about our expanded patents for Adva-27a.” 

About Sunshine Biopharma’s Coronavirus (COVID-19) Treatment

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

About Sunshine Biopharma’s Adva-27a Anticancer Drug 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time.

For Additional Information Contact: Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] www.sunshinebiopharma.com 

Nutrition.SunshineBiopharma.com

For Immediate Release May 4, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of oncology and antiviral drugs, today announced that it has timely filed a nonprovisional patent application in the form of a PCT in the United States for its COVID-19  treatment under development. Sunshine had originally filed a provisional patent application  covering the COVID-19 treatment on May 22, 2020. This priority date has been maintained in the  newly filed PCT application. 

In addition to the original subject matter pertaining to inhibitors of the Main Coronavirus protease,  Mpro, the PCT application contains data and extends coverage to include the Papain-Like  Coronavirus protease, PLpro. The latter is an important antiviral target as it is involved in  suppression of the host immune system thereby leading to more severe illness. 

The etiologic agent of the current COVID-19 global pandemic is Severe Acute Respiratory  Syndrome Coronavirus 2 (SARS-CoV-2), one of several strains of Coronavirus capable of  infecting humans and causing serious illness. SARS-CoV-2 produces several functional proteins  in infected human cells by cleaving them from two overlapping viral polyproteins, pp1a and pp1ab.  One of these functional proteins is a cysteine protease referred to as the main protease, Mpro (also called 3CLpro and nsp5). In addition to Mpro, a second cysteine protease, called PLpro, is  generated. Mpro and PLpro cleave the viral polyproteins at a number of specific sites thereby  generating several mature proteins essential for viral replication. PLpro also cleaves certain host  cell proteins resulting in suppression of the immune system and elevated morbidity. Because of  their functional indispensability in viral replication, Mpro and PLpro are attractive targets for the  development of anti COVID-19 therapy. 

In collaboration with the University of Georgia, College of Pharmacy, Sunshine has been pursuing  the development of several PLpro inhibitors and currently has two drug candidates of such under  evaluation in hACE2-transgenic mice. Sunshine anticipates that the COVID-19 treatment under  development will also be effective against the variants of concern. 

“The PCT represents a major milestone for our COVID-19 treatment project, as it strengthens our  intellectual property position and allows us to file patents on a worldwide basis going forward,”  said Dr. Steve Slilaty, CEO of Sunshine Biopharma.

About Sunshine Biopharma’s Coronavirus (COVID-19) Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.2 million people worldwide since  it first appeared in December 2019. There are currently no drugs that can effectively arrest  replication of the virus in people who have contracted the illness. Sunshine Biopharma has  completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead  compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive  license agreement with the University of Georgia for two Anti-Coronavirus compounds which the  University of Georgia had previously developed and patented. The Company is currently  advancing the development of these two compounds in parallel with its own SBFM-PL4 by  conducting a transgenic mice study in collaboration with the University of Georgia, College of  Pharmacy. The mice being used in the study have been genetically engineered to express the  human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making  them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2  receptor to gain entry into human cells to replicate. The goal of the study is to determine if these  protease inhibitors will protect the hACE2-transgenic mice from disease progression and death  following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine  Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual  COVID-19 patient volunteers in a Phase I clinical trial setting. 

About Adva-27a Anticancer Drug 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date  have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner  of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time.

For Additional Information Contact: Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected]

www.sunshinebiopharma.com

For Immediate Release April 22, 2021

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of oncology and antiviral drugs, today announced that RB Capital has injected an additional investment of $500,000 to augment the Company’s Coronavirus drug  development program. In addition, RB Capital has provided the Company with assurances that  it will continue to provide funding over the next 30 days for the Company’s other R&D activities,  including Ada-27a anticancer drug. 

Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are very pleased to continue our  relationship with RB Capital as long-term investor in the Company. They truly understand our  vision and are prepared to help us reach our exciting drug development objectives.” 

Deborah Braun of RB Capital Partners Inc. stated, “Given their recent success with initial mice  studies for their COVID-19 treatment, the tremendous progress with Adva-27a research and development, and the new e-commerce platform, we are happy to double our investment in  Sunshine Biopharma. We understand that financial resources are required to reach the various  milestones leadership has put into place for the Company and are pleased to support this  growth and progress. With this added investment the Company has the resources necessary to  bring these drugs to market faster than previously anticipated.” 

About Sunshine Biopharma’s Coronavirus (COVID-19) Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3 million people worldwide since  it first appeared in December 2019. There are currently no drugs that can effectively arrest  replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a provisional patent application for several molecules which were designed by  computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of  the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such  molecules and identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine 

Biopharma entered into an exclusive license agreement with the University of Georgia for two  Anti-Coronavirus compounds which the University of Georgia had previously developed and  patented. The Company is currently advancing the development of these two compounds in  parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the  University of Georgia, College of Pharmacy. The mice being used in the study have been 

genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2)  transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV 2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate.  The goal of the study is to determine if these protease inhibitors will protect the hACE2- transgenic mice from disease progression and death following infection with SARS-CoV-2.  Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to  the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I  clinical trial setting. 

About Adva-27a Anticancer Drug 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to  date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant  Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer  cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to  be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine  Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

For Immediate Release April 19, 2021

Montreal, Quebec, Canada — (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has successfully completed a Maximum Tolerated Dose (MTD) study in mice. Sunshine Biopharma is pleased to report that the MTD results are favourable and fall within the optimum range for use in humans. 

Next, Sunshine Biopharma will use the test dose indicated by these results to conduct the efficacy studies in hACE2-transgenic mice. 

Sunshine Biopharma’s COVID-19 treatment is an inhibitor of PLpro, a protease present only in the  SARS Coronaviruses (Betacoronaviruses) and is an important antiviral target as it is involved in shutting down the host innate immune system thereby causing significantly greater morbidity. 

“MTD is defined as the highest dose of a drug that does not cause unacceptable side effects or overt toxicity in a specific period of time. The MTD studies we conducted were designed with a  minimum number of animals and included endpoints such as clinical observations and blood tests for liver function,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are delighted that our compounds passed this critical toxicology step with flying colors,” he added. 

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a patent application for several molecules which were designed to inhibit the Coronavirus  PLpro protease, thus shutting down the ability of the virus to multiply. PLpro is present only in the SARS  Coronaviruses (Betacoronaviruses) and is an important antiviral target as it is involved in shutting down the host’s innate immune system. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two additional Anti-Coronavirus compounds which the  University of Georgia had previously developed and patented. Sunshine Biopharma is currently advancing the development of these two compounds in parallel with the Company’s own (SBFM-PL4) by conducting a transgenic mice study in collaboration with the University of Georgia. The goal of the ongoing study is to determine if our protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine 

Biopharma plans to submit the results to the FDA and Health Canada for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

About Sunshine Biopharma’s Anticancer Compound 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

For Immediate Release March 23, 2021

Montreal, Quebec, Canada — (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received a total of  $2,054,000 to date from the recently announced committed minimum financing of $2,000,000 with  RB Capital Partners Inc. The financing is in the form of fixed-price convertible debt which now  stands at a weighted average conversion price of $0.43 per share. This debt is obligatorily convertible on or before the maturity date. 

The proceeds will be used for the ongoing development of the Company’s Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer compound targeted for pancreatic cancer. Development of both projects is currently underway and the research is progressing as planned. On February 1, 2021, Sunshine Biopharma initiated a transgenic mice study for two Anti-Coronavirus compounds in collaboration with the University of Georgia. The goal of the ongoing study is to determine if these protease inhibitors will protect  the hACE2-transgenic mice from progression to disease and death following infection with SARS 

CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA and Health Canada for authorization to conduct testing on actual COVID-19  patient volunteers in a Phase I clinical trial setting. 

Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We continue to push ahead with the development of our COVID-19 treatment in collaboration with the University of Georgia and our  Adva-27a anticancer compound with our corporate partners in Montreal. This investment is integral to our progress in both of these crucial drug development sectors.” 

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 2.7 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a patent application for several molecules which were designed to inhibit the Coronavirus  PLpro protease, thus shutting down the ability of the virus to multiply. PLpro is present only in the SARS  Coronaviruses (Betacoronaviruses) and is an important antiviral target as it is involved in shutting down the host’s innate immune system. On February 1, 2021, Sunshine Biopharma entered into an exclusive license  agreement with the University of Georgia for two additional Anti-Coronavirus compounds which the 

The University of Georgia had previously developed and patented. Sunshine Biopharma is currently advancing the development of these two compounds in parallel with the Company’s own (SBFM-PL4) by conducting a transgenic mice study in collaboration with the University of Georgia. The goal of the ongoing study is to determine if our protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine  Biopharma plans to submit the results to the FDA and Health Canada for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

About Sunshine Biopharma’s Anticancer Compound 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464

For Immediate Release March 11, 2021

Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a  pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has received a “Notice of Allowance” from the European Patent Office for a new patent application covering Adva-27a, the Company’s flagship anticancer compound. This newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United  States was issued in 2019 (US Patent Number 10,272,065) and similarly covers Adva-27a until  2033. The Canadian Intellectual Property recently issued a Notice of Allowance for the analogous patent in Canada. Sunshine Biopharma is the sole owner of all intellectual property rights pertaining to Adva-27a, including the first Adva-27a patent issued in the United States in 2012  (US Patent Number 8,236,935). 

“We are very excited about this significant extension of proprietary protection for Adva-27a,” said  Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. “With a total population of nearly 450 million people, the European Union represents a significant market for Adva-27a once approved for marketing,” he added. 

About Sunshine Biopharma’s Adva-27a 

Adva-27a is a unique anticancer compound targeted for multidrug resistant cancer. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug  Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast  Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. 

About Sunshine Biopharma and COVID-19 Treatment 

In addition, to working on the development of Adva-27a, Sunshine Biopharma is engaged in the development of a treatment COVID-19. Severe Acute Respiratory Syndrome-Coronavirus-2  (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 2.6 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modelling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. On  February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the  University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. Sunshine Biopharma is currently advancing the development of these two compounds in parallel with the Company’s own SBFM-PL4 by conducting a  transgenic mice study in collaboration with the University of Georgia. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2  (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by  SARS-CoV-2. The SARSCoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if Sunshine Biopharma’s protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with  SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. The implications of a COVID-19 treatment becoming available are vast. This is particularly the case in view of the fact that some of the variants emerging around the world are more virulent and may escape neutralization by the current vaccines. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

For Immediate Release March 4, 2021

Montreal, Quebec, Canada — (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of oncology and antiviral drugs, today announced that it has received shipment  of a new batch of Adva-27a from its manufacturer in China. The material has been delivered to  the laboratories of Sunshine Biopharma’s drug development partner in Montreal (Canada). 

Following initial QA/QC testing of the material for specific biological activity, Sunshine Biopharma  will proceed to performing tumor inhibition studies on xenograft mice harboring tumors of human  pancreatic cancer origin. Pancreatic Cancer is Sunshine Biopharma’s clinical trials indication for  Adva-27a. Among several other cancer types, Pancreatic Cancer is resistant to existing 

chemotherapy drugs but has been shown to be susceptible to Adva-27a in preclinical studies. 

“We look forward to initiating the xenograft mice studies as soon as the QA/QC testing is done.  Mice studies of this sort provide crucial information and technical guidance for the clinical trials to  be conducted in subsequent drug development events,” said Dr. Steve Slilaty, CEO of Sunshine  Biopharma. 

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19 which is now in the  transgenic mice testing phase, Sunshine Biopharma is engaged in the development Adva-27a, a  unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of  Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells,  Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for  Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General  Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual  property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming 

quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

For Immediate Release March 1, 2021

Montreal, Quebec, Canada — (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a leader in nutrition research and development today unveiled its new eCommerce website, Nutrition.SushineBiopharma.com. The site boasts over 20 products ranging from essential amino acids and rich protein powders to balanced vitamins and crucial micronutrients.  All of Sunshine Biopharma’s nutritional supplements are manufactured and tested in Canada under strict GMP conditions and Health Canada oversight. Some of the products listed on  Nutrition.Sunshinebiopharma.com will continue to be available on Amazon.com and Amazon.ca. 

Seekers of the highest quality, science-based nutritional products will enjoy the  Nutrition.SunshineBiopharma.com experience where they can easily browse the items listed,  place their order and checkout in a streamlined manner. Among the products featured on  Nutrition.SunshineBiopharma.com is Essential 9^TM, a tablet containing all 9 essential amino acids that the human body cannot produce on its own. Essential 9^TM was developed and formulated by  Sunshine Biopharma, a pharmaceutical company that has the user’s optimum health in mind. 

Now more than ever, it is critical to maintaining optimal health amidst the global pandemic. Among its many benefits, Essential 9^TM can help boost the immune system and increase overall health. In addition to Essential 9 ^TM, Nutrition.SunshineBiopharma.com offers other health promoting supplements including balanced vitamins, individual amino acids, protein, and meal replacement products. 

“In 2020, eCommerce sales in the US amounted to approximately $374 billion and are expected to reach $476 billion by 2024. We are thrilled to introduce Nutrition.Sunshinebiopharma.com,  which allows customers to shop reliable, routinely tested nutritional supplements anytime,” said  Camille Sebaaly, CFO of Sunshine Biopharma. “Our site will feature a unique assortment of the nutritional products valued by everyone. We are excited for customers to enjoy our fun, interactive  features and curations.” 

About Essential 9^TM 

Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, chronic fatigue, weight gain, and weakened immune system. Sunshine  Biopharma’s Essential-9^TM provides a balanced formula of all 9 Essential Amino Acids in free form, ready to be absorbed. Essential-9^TM is suitable for everyone: Vegans, Seniors, Dieters,  Athletes, and everyone looking to increase their health. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

For Immediate Release February 17, 2021

Phoenix, February 17th, 2021 (Newsfile Corp.) — The Stock Day Podcast welcomed  Sunshine Biopharma (SBFM)(“the Company”), a company engaged in the development of Adva-27a, a unique anticancer compound, as well as the development of a treatment for COVID-19. CEO of the Company, Dr. Steve Slilaty, joined Stock Day host Everett  Jolly.  

Jolly began the interview by commenting on the Company’s significant increase in stock  price over the past several months. “I think the market recognizes the significant  progress that we’ve been making, and we’re very excited about the science we’ve been  doing,” shared Dr. Slilaty.  

“Could you give us an update on the licensing agreement with the University of  Georgia?”, asked Jolly. “Initially, we teamed up with the University of Georgia because  they had worldwide renowned expertise in coronavirus protease inhibitors, and this is  what our coronavirus treatment is centered around,” explained Dr. Slilaty. “The  University of Georgia had two technologies which were already patented by them and  we agreed that they would license them to us on an exclusive basis. In return, we would  offer co-development of their compounds in parallel with our own.”  

Jolly then asked about the progress of the Company’s COVID-19 treatment. “We are  now at the stage where we have initiated mice studies on our SBFM-PL4 protease  inhibitor,” said Dr. Slilaty, adding that the Company will also be including the licensed  compounds from the University of Georgia in these studies. Dr. Slilaty then elaborated  on the process of the mice studies, as well as what would occur in the event of a  successful study. “If that were the case, we would file our results with the FDA and  request that the FDA authorizes us to proceed to test our compound on actual COVID 19 patients.” 

The conversation then turned to the Company’s development of Adva-27a. “So, that is  our flagship anticancer compound,” explained Dr. Slilaty. “It is the only drug we’re aware  of anywhere in the world that works on multidrug resistant cancer cells,” he shared.  “We’re really excited about this. We have ordered a new batch of Adva-27a, and we’re  expecting delivery of the new batch any time now,” said Dr. Slilaty, adding that the  Company intends to use the compound in mice studies. 

“What’s next for the COVID-19 research plan?”, asked Jolly. “At the end of the mice  studies, we’re going to file the data of the mice studies with the FDA and request a 

review of our results, as well as authorization to proceed with Phase I clinical trials on  actual COVID-19 patient volunteers,” explained Dr. Slilaty. “What’s interesting with our  drug is the fact that it can be taken orally at home. There is no need for a hospital  setting, as is the case right now with current treatments.” 

To close the interview, Dr. Slilaty thanked listeners and shareholders for their support  and interest as they continue to develop treatments for COVID-19 and cancer. “We  hope that we will make a difference in reducing the number of deaths not only in the  United States, but around the world.” 

To hear Dr. Steve Slilaty’s entire interview, follow the link to the podcast here:  https://audioboom.com/posts/7801741-sunshine-biopharma-discusses-the-progress-of-its covid-19-and-anticancer-compounds-with-the-stock 

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages  listeners to visit the company’s message board at https://investorshangout.com/ 

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine  Biopharma is engaged in the development Adva-27a, a unique anticancer compound.  Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying  Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung  Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for  Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish  General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and  intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current  expectations, forecasts, and assumptions that involve risks as well as uncertainties that  could cause actual outcomes and results to differ materially from those anticipated or 

expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and  future growth for upcoming quarterly and annual periods. These risks and uncertainties  are further defined in filings and reports by the Company with the U.S. Securities and  Exchange Commission (SEC). Actual results and the timing of certain events could  differ materially from those projected in or contemplated by the forward-looking  statements due to a number of factors detailed from time to time in our filings with the  SEC. Among other matters, the Company may not be able to sustain growth or achieve  profitability based upon many factors including but not limited to general stock market  conditions. Reference is hereby made to cautionary statements set forth in the  Company’s most recent SEC filings. We have incurred and will continue to incur  significant expenses in our expansion of our existing as well as new service lines noting  there is no assurance that we will generate enough revenues to offset those costs in  both the near and long term. Additional service offerings may expose us to additional  legal and regulatory costs and unknown exposure(s) based upon the various  geopolitical locations we will be providing services in, the impact of which cannot be  predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com

About The “Stock Day” Podcast 

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and  Micro-Cap companies. It educates investors while simultaneously working with penny  stock and OTC companies, providing transparency and clarification of under-valued,  under-sold Micro-Cap stocks of the market. Stock Day provides companies with  customized solutions to their news distribution in both national and international media  outlets. The Stock Day Podcast is the number one radio show of its kind in America. 

SOURCE: 

Stock Day Media 

(602) 821-1102

For Immediate Release February 10, 2021

Montreal, Quebec, Canada — (ACCESSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”),  a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has initiated a momentous transgenic mice study of its COVID-19 treatment that has been under development since May of last year. 

Sunshine Biopharma’s COVID-19 treatment consists of a series of small molecules which suppress replication of the virus by inhibiting a key virus encoded protease that is responsible for compromising the immune system of infected patients. The mice studies are currently underway at the University of Georgia, College of Pharmacy. 

The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2, the causative agent of COVID-19. The SARS CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if Sunshine Biopharma’s protease inhibitors will protect the hACE2- transgenic mice from disease progression and death following infection with SARS-CoV-2 virus. 

“Should these mice studies prove successful, we plan to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are excited to have initiated this pivotal study on transgenic mice with the University of Georgia. The implications of a COVID-19  treatment becoming available are vast. This is particularly the case in view of the fact that some of the variants emerging around the world are more virulent and may escape neutralization by the current vaccines,” he added. 

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the etiologic agent of the ongoing COVID-19 pandemic that has claimed the lives of over 2.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modelling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of 

Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM PL4 through the in vitro testing stage to be followed by mice studies, currently underway, before entering clinical trials on COVID-19 patients. 

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected] 

www.sunshinebiopharma.com